India: Life Sciences, Biotechnology & Nanotechnology

India's life sciences regulatory landscape in July 2026 saw major developments across pharmaceuticals, medical devices, and healthcare regulation. Key changes included the draft National Pharmacy Commission Bill proposing to replace the 80-year-old Pharmacy Act, CDSCO's final guidance on Medical Device Software establishing clear market access pathways, and stricter controls on high-alcohol oral formulations under Schedule H1.

The Union Ministry of Health and Family Welfare (the “Ministry”) has recently published a Draft Notification[1] in the Official Gazette proposing amendments to the Medical Devices Rules, 2017[2] (the “Rules”), promulgated under the Drugs and Cosmetics Act, 1940. The proposed amendments specifically target the statutory timelines prescribed for processing manufacturing licence applications across the four risk-based classifications of medical devices.

Patent pendency remains one of the most significant challenges in U.S. patent prosecution. Average first-action wait times range from approximately 20 to 29 months across Technology Centers, creating real costs for startups seeking investor credibility, life sciences companies racing toward product launches, and technology firms defending competitive market position.

On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to acquire all outstanding shares of Organon...

The life sciences and healthcare industry in India continues to evolve through regulatory and policy developments. In March 2026, key developments included proposed frameworks for post-approval...

On March 25, 2026, the National Pharmaceutical Pricing Authority (NPPA), operating under the aegis of the Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals), Government of India...

In the past couple of months, the healthcare and pharmaceutical sectors have undergone a series of structural reforms and policy adjustments, highlighting a clear focus on enhancing patient-centricity, standardising quality benchmarks, and streamlining regulatory compliance.

The Hon'ble Delhi High Court in the matter of Samarendra Das v. Win Medicare Pvt. Ltd., 2025 SCC OnLine Del 6347, reaffirmed that a medical or sales representative employed in the pharmaceutical sector does not qualify as a "workman" under Section 2(s) of the Industrial Disputes Act, 1947 ("Act").

Welcome to the August 2025 edition of our Life Sciences and Healthcare Newsletter, where we delve into the latest developments shaping the industry.